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Abstract: Overactive bladder (OAB) syndrome is a common, complex, and challenging condi-
tion. To assist the management of these patients, the European Association of Urology (EAU) 
updates its guidelines annually. This review reports the presentations from the symposium titled 
“Dealing with complex OAB patient profiles: in or out of the EAU guidelines?” held at the 32nd 
EAU Annual Congress in March 2017 in London. The symposium focused on three groups of 
OAB patients: women who may also suffer pelvic organ prolapse, stress urinary incontinence, 
the genitourinary syndrome of menopause (GSM); patients at risk of cognitive impairment; and 
elderly patients. The aim of the symposium was to determine how the 2017 EAU guidelines 
can best assist physicians, as well as to assess the benefits of fesoterodine in these patients. The 
EAU guidelines recommend antimuscarinic agents (grade A) for the medical treatment of OAB. 
In women, OAB is correlated with GSM, both of which are underdiagnosed and undertreated. 
Fesoterodine decreases OAB symptoms and the associated limitation of physical activity. A 
combination of fesoterodine and vaginal estrogens is appropriate for OAB associated with GSM. 
In patients at risk of cognitive impairment, prescribers should pay particular attention to the 
choice of medication. Fesoterodine is a Pgp substrate with limited ability to cross the blood–brain 
barrier, which may explain the lack of negative effects on the central nervous system observed 
in clinical trials of this agent. OAB should not be regarded as a normal consequence of aging. 
Fesoterodine has been extensively investigated in the elderly, and is the only anticholinergic 
drug licensed for OAB in this population, rated B (beneficial) according to the Fit for the Aged 
classification for lower-urinary-tract symptoms. The EAU guidelines are a valuable resource for 
physicians managing patients with OAB, and the pharmacological properties of fesoterodine 
offer credible clinical advantages in these three patient groups.
Keywords: cognitive function, elderly, fesoterodine, guidelines, overactive bladder, women
Introduction
Overactive bladder (OAB) syndrome is defined as “urinary urgency, with or without 
urgency urinary incontinence [UUI], usually with increased daytime frequency and 
nocturia, in the absence of infection or other obvious pathology”.1,2 OAB can be a 
complex and challenging syndrome in certain patient groups. The prevalence of OAB 
is increasing worldwide in association with the growth of the aging population, with 
11% of the global population affected in 2008 and predicted to increase to 20%, or 546 
million individuals, by 2018.3 OAB has a greater impact on the social and functional 
domains of quality of life (QL) than that of diabetes.4
The diagnosis and management of OAB merits particular attention, given that this 
syndrome can affect many patient groups: both men and women, those with other 
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comorbidities, and those taking a mix of medications.5 As 
a result, the onus is on the physician to collect an accurate 
history, examine the patient, and investigate if other causes 
can better explain the symptoms, and then to treat the patient 
accordingly. The European Association of Urology (EAU) 
guidelines6 have been developed to assist health-care profes-
sionals in dealing with complex cases in a structured way 
based on the available evidence. These are updated every year, 
and form a framework for clinicians to assist in the diagnosis 
and management of OAB.
This review reports on lectures given at the symposium 
“Dealing with complex OAB patient profiles: in or out of the 
EAU guidelines?” held at the 32nd Annual Congress of the 
EAU in March 2017 in London. The symposium, sponsored 
by Pierre Fabre Laboratories, aimed to answer the question: 
Do these guidelines help the physician in dealing with chal-
lenging patient groups, or should we vary from them? It 
focused on three challenging patient groups: women who may 
also suffer from pelvic organ prolapse (POP), stress UI (SUI) 
or the effects of menopause; OAB patients at risk of cognitive 
impairment; and elderly patients, in whom the prevalence 
of OAB is high and whose specificities are important to 
consider. The EAU recommendations for these three patient 
groups, as well as the published evidence on fesoterodine,7 
an antimuscarinic agent, are presented and discussed.
Management of women with OAB
OAB is frequently unrecognized in 
women
Data collected in Belgium from women aged 40 years or 
over visiting their general practitioner for any reason who 
answered the Bladder Control Self-Assessment Question-
naire (B-SAQ) revealed that 18% of them were affected by 
moderate–severe SUI and a third had mild bladder-control 
symptoms.8 In this study, urgency and nocturia were found 
to be the most bothersome (higher score of bother on the 
B-SAQ) symptoms. In another study,9 women from the Finn-
ish population register were contacted to assess the bother 
associated with 12 different lower-urinary-tract symptoms 
(LUTS). From an individual perspective, UUI was found 
to be the symptom most likely to be rated as bothersome by 
patients and SUI was second. Women and men with OAB 
symptoms report that OAB affects their health-related QL 
(HRQL): they have significantly poorer work productivity, 
sexual satisfaction, higher rates of major depressive symp-
toms, and less physical activity than controls.10,11 Despite this, 
many women do not seek medical assistance,9,12 leaving the 
disorder unrecognized.
OAB is a dynamic disease, particularly in 
women
In Austria, women with OAB (21–81 years) were followed 
for a mean of 6.5 years. The prevalence of OAB was 19% at 
baseline and 27% at the end of the study. With time, remis-
sion occurred in 40% of women, improvement occurred in 
12%, disease was stable in 41%, and it progressed in 7%. 
Therefore, natural history shows that OAB is a dynamic 
disease that can have a long-lasting and stable course, remit, 
or progress with age.13
Sex differences in OAB show that women 
are more often bothered by symptoms
The OAB prevalence found in the EPIC study was 12%, and 
it reached 16% in the National Overactive Bladder Evaluation 
(NOBLE) program in the US, with no significant differences 
between women and men. However, the type of symptoms 
may differ. For instance, UI seems to be more frequent in 
women (13% versus 5% in men in the EPIC study). Women 
(66%) were more likely to be bothered by frequency of urina-
tion than men (46%).14
Specific risk factors for women
In Sweden, OAB prevalence, measured in female twins from 
the Swedish twin registry, was 19% in those who had a history 
of gestational diabetes mellitus (GDM) and 11% in women 
without GDM. After adjusting for age, parity, body-mass 
index (BMI), DM, and smoking, GDM was associated with 
almost-doubled odds of OAB (OR 1.88, 95% CI 1.26–2.8).15
A systematic review of observational studies on OAB and 
metabolic syndrome, a cluster of risk factors that includes 
central obesity, dyslipidemia, hypertension, insulin resis-
tance, and glucose intolerance, concluded that there was a 
link between OAB and metabolic syndrome.16 Women with 
a BMI >30 are twice as likely to have OAB with urge incon-
tinence than women with a BMI <24.14 Weight loss should 
be encouraged, in addition to therapy for OAB symptoms.
In a cross-sectional Dutch study,17 POP symptoms were 
present in 11% of women. The prevalence of urgency, fre-
quency, UI, or any OAB symptoms was significantly increased 
in those with POP. Treatment of this independent risk factor 
was able to improve OAB symptoms. The other risk factors 
found in this study were incontinence surgery in the past, age 
>75 years, overweight, and postmenopausal status.
Genitourinary syndrome of menopause (GSM), formerly 
called vulvovaginal atrophy (VVA), has been designated 
to facilitate the identification of VV and urinary estrogen 
 deprivation-associated signs and symptoms. GSM includes 
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genital symptoms of dryness, burning, and irritation; 
impaired sexual function with lack of lubrication, discomfort, 
or pain; and urinary symptoms with frequency, nocturia, 
urgency, SUI, and urinary-tract infections when other vul-
var and urinary pathologies possibly responsible for similar 
symptomatology have been excluded.18
The female lower urinary tract is a target organ for 
estrogens, and estrogen deprivation leads to changes in peri-
urethral tissues (decrease in collagen) and urethral mucosa 
(atrophy). This could be the rationale for the use of estrogen 
supplementation in the treatment of the LUTS disorders of 
postmenopausal women.19,20 In the AGATA study,21 among 
postmenopausal women asking for a routine gynecological 
examination, 79% were diagnosed with GSM based on the 
patient’s sensation of vaginal dryness, any objective sign of 
VVA and a pH >5. Patients also reported dyspareunia (78%), 
burning (57%), itching (57%), and dysuria (36%). Only 30% 
of participants had been previously diagnosed with VVA. 
GSM appeared to be highly prevalent, underdiagnosed, and 
inadequately treated. Conserved sexual function may prevent 
or delay the loss of vaginal elasticity.21 In another study22 in 
45- to 60-year-old women, vaginal dryness was associated 
with a greater OAB prevalence (ratio 1.75, P=0.012). Health 
professionals should adopt a proactive response to women 
with genital atrophy to identify and treat OAB.
Robinson et al23 reported that 70% of women relate the 
onset of UI to their final menstrual period, corresponding to 
estrogen decrease. First-line therapies include vaginal mois-
turizers and lubricants;24 however, estrogen therapy remains 
the standard therapy for symptomatic women who suffer 
from moderate–severe GSM. Local treatment is preferred. 
There are few absolute contraindications for estrogen use, 
especially if used topically.25 Even in breast cancer patients, 
there are now data suggesting that ultralow-dose topical 
estriol can be used safely, with excellent results in improving 
vaginal microflora, quality of sex life, and urinary function.26 
The estrogen–antimuscarinic combination could be a good 
option to treat OAB in women with GSM.
Fesoterodine in women with OAB
The primary goals of pharmacological therapy for women 
with OAB are to relieve symptoms and improve HRQL. In a 
pilot study,27 menopausal patients with OAB symptoms were 
treated either with fesoterodine 4 mg/day for a week and then 
with 8 mg/day if tolerance was good, or with the same dos-
age of fesoterodine combined with topical vaginal estrogens 
once daily. After 12 weeks, the fesoterodine-alone group 
showed a significant improvement in OAB symptoms, as 
measured with the Overactive Bladder Questionnaire –short 
form (P<0.0001), HRQL (P=0.0002), and Sexual Quality of 
Life – female (SQOL-F; P=0.02). Compared to fesoterodine 
alone, the combination group showed a reduction in OAB-
symptom severity (10 versus 23.3, P=0.35), higher HRQL 
score (96.9 versus 84.6, P=0.75), and higher SQOL-F score 
(99 versus 81, P=0.098).
In a prospective study,28 women with OAB were treated 
with flexible doses of fesoterodine combined with behavioral 
counseling over 8 weeks. Physical activity was assessed using 
two questions of the Short Form 12 and categorized into three 
levels of limitation: none, moderate, or severe limitations. 
Women treated with fesoterodine reported less bother from 
urinary symptoms and fewer restrictions in physical activity, 
showing that fesoterodine reduces the impact of OAB on 
physical activity.
The SAFINA29 trial defined the goals of OAB patients, 
mainly women (80%), using the Self-Assessment Goal 
Achievement questionnaire. Patients were treated with flex-
ible doses of fesoterodine for 12 weeks. Patients’ treatment 
aims were more focused on the completion of tasks, rather 
than on reducing particular symptoms. With regard to symp-
toms, the most frequently expressed goals were to reduce 
nocturia, urgency, and frequency. At the end of the study, 
81% of patients treated with fesoterodine declared that their 
goals were “somewhat achieved”, “achieved”, or “greatly 
exceeded/exceeded their expectations”.
EAU guidelines for OAB
The 2017 EAU guidelines6 for women presenting with UI 
recommend (after initial assessment and discussion of OAB 
management) that patients are offered individual behavioral 
and physical therapies. When medical treatment is advised, 
antimuscarinic agents are recommended (grade A). The EAU 
recommendations dedicated to women meet the conclusions 
of the studies presented, notably:
•	 on risk factors: “Encourage obese women with UI to lose 
weight and maintain weight loss (grade A)”
•	 on activity: “Counsel female athletes experiencing UI 
with intense physical activity that it will not predispose 
them to UI in later life (grade C)”
•	 on estrogen therapy: “Offer postmenopausal women 
with UI vaginal estrogen therapy, particularly if other 
symptoms of VVA are present (grade A)”; “Vaginal 
estrogen therapy for VVA should be prescribed long-term. 
In women with a history of breast cancer, the treating 
oncologist needs to be consulted (grade C)”.
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Dealing with OAB in patients at risk 
of cognitive impairment
Specific factors in patients at risk of 
cognitive impairment
Being prefrail or frail, having a functional comorbidity index 
(number of comorbidities 0–18) ≥2, and being aged ≥85 
years have been found to be associated with anticholinergic 
medication use.30 However, one of the major issues of treating 
these patients is the difficulty in assessing their exposure to 
and impact of drugs with anticholinergic effects. The serum 
anticholinergic assay has been proposed as a measure of 
anticholinergic burden, but assay levels do not necessarily 
reflect the treatment used by the patient.30 Few patients report 
central nervous system (CNS) symptoms, because they are 
not able to recognize the cognitive impairment or changes 
in memory or may think these are related to aging and not 
to their medications.31 The effects of anticholinergics on 
cognition vary substantially among studies. This may be 
due to several factors, including age, clinical condition, and 
the medicines used.30,32 Recognition of how many drugs the 
patient is taking and the variety of different therapeutic areas 
they involve, including antihistamines, antidepressants, anti-
emetics, antipsychotics, muscle relaxants, and antivertigo, 
cardiovascular, gastrointestinal, or antiparkinsonian drugs, 
which have anticholinergic properties33 is important, and they 
should be identified as such. Patients can be considered at 
risk of cognitive impairment where there is preexisting CNS 
impairment or when they take multiple medications or some 
with anticholinergic activity, particularly when oxybutynin 
is used in vulnerable elderly patients.31,34
The role of the blood–brain barrier
The blood–brain barrier (BBB) is a complex, heterogeneous, 
and dynamic membrane at the level of the cerebral capillaries 
that limits the entry of unwanted molecules into the brain. 
Antimuscarinic agents cross the BBB via passive diffusion 
according to their lipophilicity and molecular weight.34–38 
Some antimuscarinics are removed from the brain via an 
active transport mechanism facilitated by Pgp, which limits 
the levels of drugs in the brain. The BBB can be impaired 
by different causes, including aging, medication, or systemic 
diseases (inflammatory; neurodegenerative diseases, such 
as Alzheimer’s, Parkinson’s disease, and multiple sclerosis; 
vascular conditions; neoplasia; brain edema; meningitis; 
and trauma).34,39
Fesoterodine in OAB patients at risk of 
cognitive impairment
As a result of its pharmacological properties, fesoterodine 
crosses the BBB poorly, which in fact is an advantage in 
terms of any potential negative effect on cognitive function. 
It has the highest molecular weight of the antimuscarinics 
and low lipophilicity (Table 1); moreover, the active moiety 
of fesoterodine, 5-HMT, is pumped out of the brain by Pgp, 
an efflux transporter.7,33,38,40–42 Trospium is a quaternary amine 
and a hydrophilic molecule that does not cross the BBB.
The effect of fesoterodine on cognitive function has 
been evaluated in a crossover study43 where healthy older 
individuals (mean age 72.2 years) received over four differ-
ent periods fesoterodine 4 mg × 6 days, fesoterodine 4 mg 
× 3 days + fesoterodine 8 mg × 3 days, placebo × 6 days, or 
placebo × 6 days with alprazolam 1 mg on day 6. A battery 
of cognitive tests (detection task, identification task, one-
card learning task, continuous paired-associate learning 
task, Groton maze learning task, and the Rey auditory verbal 
learning test) were performed on days 1 and 6 of each period. 
Unlike alprazolam, which induced sedation and a large and 
statistically significant deterioration, fesoterodine at doses 
of 4 mg and 8 mg showed no statistically significant effects 
compared with placebo on any of the cognitive functions, 
including memory.
The effects of flexible-dose fesoterodine were tested 
in a double-blind, placebo-controlled Vulnerable Elderly 
Study.44 Vulnerable elderly subjects were defined as having 
a risk of deteriorating health with a score ≥3 on the Vulner-
able Elders Survey (VES) 13 and a score ≥20 on the Mini-
Mental State Examination (MMSE), indicating possible mild 
cognitive impairment (MMSE maximum score 30, scores 
≥27 correspond to normal cognition, 20–26 indicate some 
cognitive impairment). In both the placebo and fesotero-
Table 1 Pharmacological and pharmacokinetic properties of antimuscarinic agents
Molecules Oxybutynin Tolterodine Trospium Propiverine Darifenacin Solifenacin Fesoterodine/5-HMT
Molecular weight 393.9 475.6 427.97 403.95 507.5 480.55 527.66
Lipophilicity >3.3 1.83 –1.22 Lipophilic 2.7 1.69 0.74
Pgp substrate No No Yes No Yes No Yes
Notes: Data from Chancellor and Boone,31 Cetinel and Onal,33 Kerdraon et al,38 Malhotra et al.42 Copyright © 2011. MHRA. Adapted from Medicines and Healthcare 
Products Regulatory Agency. Public assessment report – mutual recognition procedure: Mictonorm XL 45 mg modified release capsules (propiverine hydrochloride). 2011. 
Available from: http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con143796.pdf.40
Abbreviation: HMT, hydroxymethyl tolterodine.
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dine groups, patients had a high number of comorbidities 
(mean number per patient slightly over eight, range one to 
27) and  comedications (mean number per patient slightly 
over eight, range one to 40). Treatment with a flexible dose 
of fesoterodine over 12 weeks showed significantly greater 
efficacy versus placebo in reducing the mean number of 
UUI episodes and micturitions per 24 hours. There was 
no decrease in mean MMSE scores for subjects receiving 
fesoterodine or placebo, showing that fesoterodine did not 
worsen cognitive impairment. Fesoterodine was well toler-
ated, with a safety profile comparable to that seen in other 
studies in younger populations. The most frequent adverse 
events were a dry mouth and constipation, and no new safety 
signals were identified.
2017 EAU guidelines and cognitive 
function
The 2017 EAU guidelines contain a specific chapter dedicated 
to antimuscarinic agents, the elderly, and cognition, and 
recommend caution notably in the long-term use of antimus-
carinic treatment in elderly patients, especially those who 
are at risk of, or have, cognitive dysfunction. Moreover the 
total antimuscarinic load has to be evaluated and if additional 
antimuscarinic load is to be avoided the use of mirabegron 
should be considered.6
Concerning antimuscarinic agents, the EAU guidelines 
state that “solifenacin, darifenacin, fesoterodine, and tros-
pium have been shown not to cause cognitive dysfunction 
in elderly people”.6
Elderly with OAB
Specific factors in elderly patients with 
OAB
Although the prevalence of OAB increases with age, it should 
not be considered a normal consequence of aging.45 Treat-
ment should be chosen on an individual basis, taking into 
account tolerability, absence of drug interactions, and cogni-
tive safety.46 OAB and UUI in the elderly may have serious 
consequences, notably in cases of nocturia. Elderly women 
with UI have a 26% higher risk of falls and 34% greater risk 
of fractures. Urgency and UUI significantly predict 10-year 
mortality in men, and UUI significantly predicts mortality 
in women.47–49 The OAB Re-Contact Study, a self-reported 
Internet survey in patients aged 65 years or over, demon-
strated that diagnosed versus undiagnosed and treated versus 
untreated respondents had better mental scores, better QL, 
and less impairment of their activity.50
Fesoterodine in elderly patients
Fesoterodine possesses four interesting pharmacological 
properties that give it a therapeutic profile adapted to many 
OAB patients, including the elderly.51–53 Firstly, fesoterodine’s 
active metabolite, 5-HMT, has limited ability to cross the 
BBB, and as a Pgp substrate, it is actively pumped out of the 
brain. As a result, fesoterodine presents a safe profile with 
respect to cognitive impairment. Secondly, the molecule does 
not undergo first-pass hepatic metabolism, but is metabolized 
by ubiquitous peripheral esterases that are not dependent on 
the individual’s enzymatic equipment and not affected by 
age. This property might explain the consistency of response 
across patients and the consistent results in clinical trials. 
Thirdly, fesoterodine is a prolonged-release medication, 
permitting once-daily dosing. Finally, fesoterodine has a 
balanced affinity for M
2
 and M
3
 receptors. All muscarinic-
receptor subtypes have been detected in the human bladder; 
however, the M
2
 and M
3
 receptors seem to be the most 
important in the regulation of the complex process of blad-
der function. The M
2
 subtype outnumbers the M
3
 subtype, 
and is the most highly expressed in the urothelium of the 
human bladder. However, M
3
 receptors are thought to be 
most important for detrusor contraction, which is decreased 
in cases of blockade by anti-M
3
 agents.54,55 Both subtypes are 
coupled to G proteins, but their signal-transduction pathways 
differ54 (Figure 1). Activation of M
2
 receptors reverses the 
sympathetic β-adrenoreceptor-mediated relaxation of the 
detrusor. Therefore, by blocking M
2
 receptors with M
2
 anti-
muscarinic agents, fesoterodine inhibits this effect, resulting 
in bladder relaxation and an increase in bladder capacity.56 
The M
2
 receptor might also play an indirect role in mediating 
Figure 1 Actions of acetylcholine on M2 and M3 receptors.
Notes: Stimulation of M3 receptors activates PLC and phosphoinositide hydrolysis, 
leading to inositol triphosphate (IP3) and diacylglycerol (DAG) formation, inducing 
calcium release and detrusor contraction. M2 receptors inhibit AC, and may aid 
bladder contraction by reversing cAMP-induced relaxation. Data from Abrams and 
Andersson,54 Sellers and Chess-Williams,55 and Chapple.56
Abbreviations: ACh, acetylcholine; cAMP, cyclic adenosine monophosphate; NA, 
noradrenaline;  β3, beta-3 adrenergic receptor; M2, M3, muscarinic receptors.
IP3/DAG
Contraction Relaxation
M3
M2 β3PLC
ACh
NA
AC
Other effects cAMP
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bladder contraction by enhancing the contractile response 
to M
3
-receptor activation, and minor M
2
-receptor-mediated 
contractions might also occur. Moreover, in some disease 
states, the contribution of M
2
 receptors to detrusor contrac-
tion might increase.54 The result of fesoterodine’s balanced 
M
2
–M
3
 affinity is a double effect on contraction control and 
relaxation.
Several studies have evaluated the efficacy and safety of 
fesoterodine in elderly OAB patients. In the SOFIA study in 
an aging population,57 patients aged 65 years or older were 
randomized to fesoterodine or placebo and treated for 12 
weeks. Approximately a third of participants were older than 
75 years. At week 4, 52% of patients treated with fesoterodine 
chose to increase their dose from 4 mg to 8 mg, with a further 
16% choosing to increase their dose similarly at week 8, and 
only 4% reduced their dose during the study, supporting the 
use of flexible dosing in an elderly population. In comparison 
with placebo, fesoterodine induced a statistically significant 
decrease in urgency episodes per 24 hours, in nocturnal mic-
turitions, and incontinence-pad use, with an improvement in 
QL and a reduction in symptom-bother scores. The rate of 
severe dry mouth was low (3%).
Most of the patients who completed the SOFIA study con-
tinued in an open study for a further 12 weeks.58 The subjects 
who had received fesoterodine during the double-blind phase 
maintained the improvement in urgency episodes over the 
open-label phase, and had a lower percentage of dry mouth 
and constipation (7% and 2%, respectively, versus 28% and 
6% in the group that had received placebo in the double-blind 
phase), as well as a lower discontinuation rate due to adverse 
events (4% versus 10%). Constipation is usually considered 
an adverse event; however, in this age-group, which frequently 
shows irritable bowel disease and loose stools, constipation 
could have a positive impact and can even improve QL.59
A pooled post hoc analysis of trials60 exploring the effi-
cacy and safety of fesoterodine in elderly patients demon-
strated a significant decrease in UUI episodes per 24 hours 
in three groups (<65, 65–74, or ≥75-years of age) of patients 
treated with fesoterodine (8 mg) and a higher positive treat-
ment response (improved or greatly improved) in patients 
treated with fesoterodine (4 and 8 mg) than with placebo in 
the three age-groups, with a dose-dependent effect.
The Fit for the Aged (FORTA) classification ranks 
medical treatments according to the level of evidence pro-
vided by prospective control studies performed in elderly 
patients. This results from a systematic independent literature 
review of studies aimed at evaluating the elderly population 
through an international consensus-validation process and 
an  independent quality assessment of variation within the 
studies. The FORTA classification was first established for 
cardiology medications, and is now used for different kinds of 
treatments. It guides physicians as to the suitability of medi-
cines for older patients in an everyday clinical setting, and 
includes four categories (Table 2). In urology, FORTA-LUTS 
classifies the appropriateness of oral drugs for long-term 
treatment of LUTS in older persons. Fesoterodine is classified 
B (beneficial), and has the highest level of evidence of the 
available OAB treatments. Most of the other antimuscarinic 
agents are classified as C (careful), because the few studies 
that have been performed in aging patients were not prospec-
tive, but involved post hoc or subgroup analyses of data.61
A cost-analysis study62 evaluating the treatment costs of 
vulnerable (≥ 65 years with a VES score ≥3 and risk of deteri-
orating health) OAB patients and including fesoterodine-drug 
costs, health-care resources, and OAB-related comorbidities 
(falls/fractures, urinary tract infections, depression, and nurs-
ing home) found that fesoterodine was cost-saving compared 
to no OAB pharmacotherapy, and could save US$1,616 per 
patient per year. Fesoterodine accounted for only 4% of the 
total medical costs in the vulnerable elderly.
EAU guidelines and the elderly OAB 
patient
The word “elderly”, although not defined, usually refers to 
individuals 65 years old or over. In addition to guidelines 
Table 2 Rating of OAB medical drugs on the LUTS-FORTA 
classification
Drug class Agent FORTA class
Antimuscarinics
Darifenacin C
Fesoterodine B
Oxybutynin standard dose/
immediate release
D
Oxybutynin low dose/extended 
release
C
Propiverine D (C)*
Solifenacin C
Tolterodine C
Trospium C (B)*
β3-agonist
Mirabegron C
Note: *FORTA class attributed in the first round. Class A (absolutely), indispensable 
drug, clear-cut benefit in terms of efficacy:safety ratio proven for a given indication 
in older people; class B (beneficial), drugs with proven or obvious efficacy in older 
people, but limited extent of effect or safety concerns; class C (careful), drugs with 
questionable efficacy/safety profiles in older people, to be avoided, or omitted in 
the presence of too many other drugs, lack of benefits, or emerging side effects – 
review/find alternatives; class D (do not), avoid in older people, omit first, review/
find alternatives.
Abbreviations: FORTA, Fit for the Aged; LUTS, lower-urinary-tract symptoms; 
OAB, overactive bladder syndrome.
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related to cognitive function that also frequently concern 
elderly patients, the 2017 EAU guidelines recommend 
that older people being treated for UI should be prescribed 
nonpharmacological treatments first (grade C). They also 
consider that antimuscarinic drugs are effective in elderly 
patients (grade 1B). With natural aging, UI becomes more 
common and elderly people may require special consider-
ation and specific interventions, taking into account their 
preferences, but OAB should not be considered a normal 
consequence of aging.
Discussion
Some interesting points have been raised during the discus-
sion of the specificities of the three patient groups in light of 
the existing fesoterodine clinical data and the EAU recom-
mendations. In women, OAB is correlated with GSM, and 
both are underdiagnosed and undertreated. Antimuscarinics 
are classed as grade A in the recommendations for treatment 
of women with OAB. Fesoterodine is associated with a reduc-
tion in OAB symptoms, as well as in perceived limitations 
in physical activity. Fesoterodine combined with vaginal 
estrogens is appropriate for women with OAB associated 
with GSM.
In all patients, and particularly patients at risk of cognitive 
impairment, prescribers should be careful with medications. 
Fesoterodine has a limited ability to cross the BBB and is 
also a Pgp substrate, which could explain its lack of nega-
tive effects on the CNS, as confirmed by clinical evidence. 
Evaluation of cognitive function in healthy older subjects has 
confirmed that fesoterodine does not impair it.
Elderly people need careful consideration, and OAB 
should not be considered a normal consequence of aging. 
Fesoterodine offers an interesting combination of pharma-
cological properties with clinical benefits, and is generally 
well tolerated in older people. Fesoterodine has been studied 
extensively in elderly patients, and is the only OAB drug rated 
FORTA B (beneficial).61
In neurological diseases, such as multiple sclerosis, cogni-
tive impairment appears to be linked to neurological lesions 
and to the degree of disability measured with the Expanded 
Disability Status Scale.63 Cognitive impairment is impacted 
by the deterioration in neurological status that occurs in this 
disease. For Parkinson’s disease, the impact seems more 
linked to anticholinergic exposure, as these patients are very 
sensitive to the side effects of antimuscarinic drugs.64 Parkin-
son’s, multiple sclerosis, and also brain-trauma patients, who 
are sometimes young, are known to be at high risk of cogni-
tive impairment. Tests evaluating cognitive impairment are 
not routinely performed, and remain within the competence 
of specialists or appropriately trained physicians.
Another point raised was to determine if drug-induced side 
effects persist over the duration of treatment or if they recede after 
a certain time. In a study65 investigating the rate of dry mouth in 
female patients treated with fesoterodine, a greater proportion of 
women with dry mouth reported improvement in their urinary 
symptoms, and the authors suggested that dry mouth may be a 
marker of pharmacological potency. In clinical practice, increas-
ing the fesoterodine dose from 4 mg to 8 mg is generally associ-
ated with an increase in the rate of dry mouth; however, women 
who are satisfied with the improved control of their symptoms 
may be less troubled by a dry mouth. Usually, there is a balance 
between efficacy and side effects, which are better tolerated when 
the patient shows a better response, although important individual 
variations are observed. The response to treatment is rapid, with 
the full effect reached at 2–4 weeks. In this respect, in most 
countries, and especially in the UK, nurses have the skills and 
can take the time to explore their patients’ needs and expectations 
and explain the possible side effects. Specialist nurse intervention 
in the management of incontinence has been evaluated in several 
studies, some showing more active detection of patients, gain 
in QL, or reduction of symptoms, with high patient satisfaction 
and cost-effectiveness.66 Overall, clinical experience has shown 
that side effects seem to decrease with time, possibly because of 
the natural course of the disease, and because the patient adapts 
their treatment accordingly. Prospective studies evaluating the 
evolution of side effects after 5 or 10 years have not yet been 
performed; however, long-term treatment (24 and 36 months) 
with fesoterodine has been shown to be well tolerated, with no 
new safety concerns identified.67
Our objective here was to discuss the EAU guidelines, 
though guidelines on UI are available from other societies, 
such as the National Institute for Health and Care Excellence 
(NICE, UK) or the American Urologic Association (AUA). 
These guidelines, which may vary in their recommendations, 
were compared by Syan and Brucker68 in 2016.
Conclusion
OAB can be complex in its presentation, and occurs as part 
of a broader patient profile. The updated EAU guidelines 
are valuable in assisting physicians with the management 
of these complex patients. An appropriate assessment of the 
patient is a prerequisite to applying the EAU guidelines in 
complex groups of patients, including women who have spe-
cific risk factors and conditions; patients at risk of  cognitive 
 impairment who may have comorbidities, take multiple 
 medications, or show BBB deterioration; and elderly patients 
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who are frequently frail and vulnerable and should be treated 
with caution. Fesoterodine at doses of 4 mg and 8 mg have 
been studied extensively in these three patient groups, and has 
been shown to have pharmacological properties that confer 
clear clinical advantages: fesoterodine is efficient, irrespec-
tive of sex or age, is well tolerated in older and vulnerable 
patients, and does not cause impairment in cognitive function.
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